AADI VS SY Stock Comparison

Performance

AADI
10/100

AADI returned -64.24% in the last 12 months. Based on SPY's performance of -13.86%, its performance is below average giving it a score of 10 of 100.

SY
100/100

SY returned 60.01% in the last 12 months. Based on SPY's performance of -11.17%, its performance is above average giving it a score of 100 of 100.

Technicals

AADI
57/100

AADI receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

SY
43/100

SY receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

AADI
10/100

AADI has missed earnings 9 times in the last 20 quarters.

SY
10/100

SY has missed earnings 9 times in the last 20 quarters.

Profit

AADI
13/100

Out of the last 20 quarters, AADI has had 2 profitable quarters and has increased their profits year over year on 2 of them.

SY
46/100

Out of the last 20 quarters, SY has had 12 profitable quarters and has increased their profits year over year on 4 of them.

Volatility

AADI
39/100

AADI has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.

SY
55/100

SY has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

Sentiment

AADI

"Sentiment" not found for AADI

SY
73/100

SY had a bullish sentiment score of 73.33% across Twitter and StockTwits over the last 12 months. It had an average of 1.40 posts, 0.00 comments, and 0.00 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Aadi Bioscience, Inc. Common Stock Summary

Nasdaq / AADI

Healthcare

Biotechnology

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

So-Young International Inc. American Depository Shares Summary

Nasdaq / SY

Healthcare

Medical - Healthcare Information Services

So-Young International Inc. operates an online platform for medical aesthetics and consumption healthcare services focusing on discretionary medical treatments in the People's Republic of China and internationally. Its platform enables users to discover content and share their own experience on medical aesthetics procedures and leads users to reserve treatment services from medical aesthetic service providers for offline treatment. The company facilitates research on medical aesthetic treatment trends; ratings and reviews on treatment experiences; and blogs under the name Beauty Diaries. It also provides reservation services in the areas of dermatology, dentistry and orthodontics, ophthalmology, physical examinations, gynecology, human papilloma virus vaccines, and postnatal care; Software as a Service; and guiding and consulting services through training programs for medical service providers. In addition, the company offers internet information and technology advisory, management consulting, and Internet culture services, as well as sells medical equipment; equipment production, sales, and agency services; and micro finance services. As of December 31, 2021, it had approximately 8,400 medical aesthetic service providers and 5,000 other consumption healthcare service providers on its platform. The company was founded in 2013 and is headquartered in Beijing, China.

Power up your portfolio